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recurrence or regrowth and clinical variables in menin-
gioma. Eighty nine patients with no corticosteroid therapy 
were included. Blood tests and tumor characteristics were 
collected from medical records. Recurrence-free survival 
was evaluated using Cox regression and Kaplan-Meier 
curves. Of the 89 cases, 73 (82%) were grade I and 16 (18%) 
grade II. The mean age was 53±13.9  years, with higher 
frequency in women, 2:1 proportion. The most frequent 
subtypes were meningothelial (40.4%), transitional (23.5%) 
and atypical (17.9%), 64% with peripheral location and 
64% had a size greater than 3 cm. Regarding tumor resec-
tion, 49 (55.1%) underwent complete surgery (40 remained 
with tumor (81.6%) and 9 relapse (18.3%)) and 40 (44.9%) 
submitted to partial resection surgery (29 remained with 
persistent lesion (72.5%) and 11 regrowth (25%)). In total, 
20 (22.4%) cases of recurrence or regrowth were observed. 
The median recurrence-regrowth free survival (RFS) was 
62 months, 96.1% at 1 year, 67.4% at 3 years and 51.2% 
at 5  years. In univariate analysis, anemia (p=0.04), 
neutrophilia (p=0.02) and neutrophilis/lymphocyts ratio 
(NLR) (p=0.03) were associated with an increased risk of 
recurrence or regrowth and poor RFS. In multivariate, the 
interaction between anemia and NLR >4 represented a 
higher risk of recurrence or regrowth (p=0.003). The pre-
operative presence of anemia, neutrophilia, and NLR was 
associated with an increased risk of recurrence or regrowth 
in meningiomas, emphasizing the importance of preopera-
tive evaluation of these parameters.
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Background: Obesity is commonly accompanied by im-
paired glucose homeostasis. Decreased glucose transport 
to the peripheral tissues, mainly skeletal muscle, leads to 
reduced total glucose disposal and hyperglycemia. TBC1D4 
gene is involved in the trafficking of GLUT4 to the outer 
cell membrane in skeletal muscle. Sulforaphane (SFN) 
has been suggested as a new potential anti-diabetic com-
pound acting by reducing blood glucose levels through 
mechanisms not fully understood (1). The aim of this study 
is to investigate the effects SFN on TBC1D4 and GLUT4 
gene expression in skeletal muscles of DIO mice, in order to 
elucidate the mechanism(s) through which SFN improves 
glucose homeostasis.
Methodology: C57BL/6 mice (n=20) were fed with a 
high fat diet (60%) for 16 weeks to generate diet induced 
obese (DIO) mice with body weights between 45–50 gm. 
Thereafter, DIO mice received either SFN (5mg/kg BW) 
(n=10) or vehicle (n=10) as controls daily by intraperitoneal 
injections for four weeks. Glucose tolerance test (1g/kg BW, 
IP) and insulin sensitivity test (ITT) were conducted (1 IU 
insulin/ g BW, IP route) at the beginning and end of the 
third week of the injection.
At the end of 4 weeks of the injection, samples of blood and 
skeletal muscles of both hindlimbs were collected. The ex-
pression levels of GLUT4 and TBC1D4 genes were analyzed 
by qRT-PCR. Blood was also used for glucose, adiponectin 
and insulin measurements.
Results: SFN-treated DIO mice had significantly lower 
non-fasting blood glucose levels than vehicle-treated mice 
(194.16 ± 14.12 vs. 147.44 ± 20.31 mg/dL, vehicle vs. SFN, p 
value=0.0003). Furthermore, GTT results indicate that the 
blood glucose levels at 120 minutes after glucose infusion in 
was (199.83±34.53 mg/dl vs. 138.55±221.78 mg/dl) for ve-
hicle vs. SFN with p=0.0011 respectively. ITT showed that 
SFN treatment did not enhance insulin sensitivity in DIO 
mice. Additionally, SFN treatment did not significantly 
change the expression of TBC1D4, and GLUT4 genes in 
skeletal muscles compared to vehicle treatment (p values 
>0.05).
Furthermore, SFN treatment did not significantly affect the 
systemic insulin (1.84±0.74 vs 1.54±0.55 ng/ml, p=0.436), 
or adiponectin (11.96  ±2.29 vs 14.4±3.33 ug/ml, p=0.551) 
levels in SFN vs. vehicle-treated DIO mice, respectively.
Conclusion: SFN treatment improves glucose disposal 
in DIO mice, which is not linked to the gene expression of 
GLUT4 and TBC1D4 and its mechanism of glucose disposal 
in skeletal muscles. Furthermore, SFN treatment did not 
improve insulin level, and the insulin sensitizer hormone 
adiponectin as potential players for enhancing insulin 
sensitivity.
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Background: Lithium is known to cause both hypo- and 
rarely hyper- thyroidism. It inhibits release of thyroid 
hormone and reduces the intrathyroidal iodothyronine/
iodothyrosine ratio. Due to direct toxic or immunostimulatory 
effect, lithium can also cause thyroiditis. Lithium-induced 
thyroiditis is a rare entity with an incidence rate of about 
1.3 cases per 1000 person-years. Given its generally pain-
less and transient nature, symptoms of thyrotoxicosis may 
erroneously be attributed to an exacerbation of mania.
Clinical Case: We report the case of a 29 y/o man with bi-
polar disorder on lithium therapy who presented with a 2 
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